Buy Dcth Stock <Working • 2025>

: Delcath reported record 2025 revenue of $85.2 million , a significant increase from $37.2 million in 2024. This was primarily driven by its HEPZATO KIT , which saw a 144% year-over-year sales surge .

: Management expects at least $100 million in revenue for fiscal year 2026. Projections suggest the company will return to profitability (estimated EPS of $0.04) by Q2 2026. buy dcth stock

: Results from the CHOPIN Phase 2 trial showed significant survival improvements for liver treatment, which may support broader adoption and inclusion in clinical guidelines. Financial Snapshot & Market Performance Google's Finance Data : Delcath reported record 2025 revenue of $85